| 1. |
Yao FY, Mehta N, Flemming J, et al. Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria. Hepatology, 2015, 61(6): 1968-1977.
|
| 2. |
Rossi M, Merli M, Lai Q, et al. Outcome after liver transplantation in patients with cirrhosis and hepatocellular carcinoma. Transplant Proc, 2007, 39(6): 1895-1897.
|
| 3. |
Xu X, Zheng SS, Liang TB, et al. Orthotopic liver transplantation for patients with hepatocellular carcinoma complicated by portal vein tumor thrombi. Hepatobiliary Pancreat Dis Int, 2004, 3(3): 341-344.
|
| 4. |
Roayaie S, Frischer JS, Emre SH, et al. Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters. Ann Surg, 2002, 235(4): 533-539.
|
| 5. |
Ji N, Weng D, Liu C, et al. Adenovirus-mediated delivery of herpes simplex virus thymidine kinase administration improves outcome of recurrent high-grade glioma. Oncotarget, 2016, 7(4): 4369-4378.
|
| 6. |
Sangro B, Mazzolini G, Ruiz M, et al. A phaseⅠ clinical trial of thymidine kinase-based gene therapy in advanced hepatocellular carcinoma. Cancer Gene Ther, 2010, 17(12): 837-843.
|
| 7. |
Mazzaferro V, Llovet JM, Miceli R, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol, 2009, 10(1): 35-43.
|
| 8. |
Rojas-Martínez A, Manzanera AG, Sukin SW, et al. Intraprostatic distribution and long-term follow-up after AdV-tk immunotherapy as neoadjuvant to surgery in patients with prostate cancer. Cancer Gene Ther, 2013, 20(11): 642-649.
|
| 9. |
Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med, 1996, 334(11): 693-699.
|
| 10. |
Zheng SS, Xu X, Wu J, et al. Liver transplantation for hepatocellular carcinoma: Hangzhou experiences. Transplantation, 2008, 85(12): 1726-1732.
|
| 11. |
樊嘉, 周儉, 徐泱, 等. 肝癌肝移植適應證的選擇: 上海復旦標準. 中華醫學雜志, 2006, 86(18): 1227-1231.
|
| 12. |
孫超, 羅清波, 盧修賢, 等. 符合米蘭標準和杭州標準的肝癌肝移植受者預后回顧性分析. 中華移植雜志(電子版), 2015, 9(2): 9-13.
|
| 13. |
劉召波, 栗光明. 肝移植術后肝癌復發防治進展. 臨床肝膽病雜志, 2021, 37(2): 267-271.
|
| 14. |
盧倩, 童翾, 湯睿. 肝癌肝移植轉化治療策略進展. 臨床肝膽病雜志, 2021, 37(2): 257-259.
|
| 15. |
謝炎, 張煒琪, 孫紀三, 等. 超米蘭標準肝癌肝移植術后腫瘤復發的綜合治療與局部治療的療效比較. 肝癌電子雜志, 2021, 8(3): 12-16.
|
| 16. |
王媒西, 趙圓圓, 魏來, 等. mTOR抑制劑對預防肝癌肝移植術后腫瘤復發的療效分析. 中華器官移植雜志, 2021, 42(9): 529-533.
|
| 17. |
王媒西, 趙圓圓, 楊博, 等. 不同抗腫瘤治療方法對肝癌肝移植術后復發轉移的療效比較. 器官移植, 2021, 12(3): 302-308.
|
| 18. |
秦小琰, 劉彥堯, 康權. 肝癌肝移植術后復發轉移的防治策略和靶向免疫治療. 器官移植, 2022, 13(2): 271-276.
|
| 19. |
Shetty K, Dash C, Laurin J. Use of adjuvant sorafenib in liver transplant recipients with high-risk hepatocellular carcinoma. J Transplant, 2014, 2014: 913634. doi: 10.1155/2014/913634.
|
| 20. |
Waidmann O, Hofmann WP, Zeuzem S, et al. mTOR inhibitors and sorafenib for recurrent heptocellular carcinoma after orthotopic liver transplantation. J Hepatol, 2011, 54(2): 396-398.
|
| 21. |
黃帆. 腫瘤免疫治療與肝癌肝移植. 肝膽外科雜志, 2021, 29(4): 257-261.
|
| 22. |
李照, 朱繼業. 免疫治療時代下的肝癌肝移植. 臨床肝膽病雜志, 2021, 37(2): 249-252.
|
| 23. |
高祥, 王祎. 腺病毒載體在腫瘤基因治療和基因疫苗領域的應用研究進展. 生物醫學轉化, 2021, 2(1): 83-88, 94.
|
| 24. |
Prieto J, Qian C, Hernandez-Alcoceba R, et al. Gene therapy of liver diseases. Expert Opin Biol Ther, 2004, 4(7): 1073-1091.
|
| 25. |
Li N, Zhou J, Weng D, et al. Adjuvant adenovirus-mediated delivery of herpes simplex virus thymidine kinase administration improves outcome of liver transplantation in patients with advanced hepatocellular carcinoma. Clin Cancer Res, 2007, 13(19): 5847-5854.
|
| 26. |
Zhu R, Weng D, Lu S, et al. Double-dose adenovirus-mediated adjuvant gene therapy improves liver transplantation outcomes in patients with advanced hepatocellular carcinoma. Hum Gene Ther, 2018, 29(2): 251-258.
|